Breaking News

Breast imaging company “Micrima” has fundraised $3.4M from Technology Venture Partners & others


Micrima is developing radiowave technology for detecting breast cancer

Bristol – Sept 02, 2016. RedNewswire/-

Micrima, a Bristol, UK-based breast imaging company, closed $3.4M in Series B funding round led by  Technology Venture Partners, Bristol & existing investors Swarraton Partners and Angel CoFund.

The company intends to use the funds to accelerate development of its technology and start commercialization towards the end of this year.

Micrima has developed a CE Mark approved radiowave imaging technology that aims to enable breast screening to become safer, comfortable and more accessible to a larger proportion of the global female population.

“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death for women in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman.

Also Read:  Outdoor Advertising Market Overview with Detailed Analysis, Competitive landscape Forecast to 2023

The company’s MARIA system received European regulatory approval in 2015 and is currently deployed in clinical trials based at several breast cancer imaging centres throughout the UK.

MARIA system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.

The second version of  MARIA is to be realeased early next year with highly enhanced funtionalities and  capable of automatically distinguish between different types of lesion.

Featured image source

WP Facebook Auto Publish Powered By :